Updated 18 July 2026

GLP-1 tablets vs injections: what should people compare?

Now that the Wegovy pill is a live UK private-prescription route, tablets and injections can be compared in a much more practical way. They still are not interchangeable, though. Route, dose ladder, food timing, price pattern and provider process all differ.

Tablet and injection ladders are separate

The oral Wegovy pill uses 1.5mg, 4mg, 9mg and 25mg. The injection route uses its own step-up pattern, commonly 0.25mg, 0.5mg, 1mg, 1.7mg and 2.4mg. Those numbers are not meant to be translated across formats. Shared active ingredient does not make the two routes dose-equivalent.

That matters because the most common comparison mistake is assuming a pill dose and an injection dose can be lined up directly. They cannot. A prescriber decides whether one route or the other is appropriate.

Daily tablet routine vs weekly injection routine

The everyday difference is the route and its medicine-specific instructions.

• Tablets: the Wegovy tablet leaflet contains fasting, water and timing requirements that affect absorption.
• Injections: weekly administration with a separate product leaflet and dose schedule.

These practical differences are worth discussing during a clinical assessment. Neither route is a dose-for-dose substitute for the other.

Absorption and consistency

The pill has stricter administration rules because absorption matters more. Taking it incorrectly can reduce how much of the medicine your body absorbs. That does not mean the route is weak; it means the instructions matter more in day-to-day use.

The injection avoids that specific problem, but it comes with its own practical barrier for people who simply do not want to self-inject.

Cost and availability trade-offs

Oral and injectable GLP-1 routes do not always move in parallel on price or availability. The Wegovy pill now has public UK provider prices, but the market is still young enough that dose coverage, introductory offers and public wording vary quite a lot from one provider page to another.

Injection routes have been part of UK weight-management conversations for longer, so some providers have more established processes around them. That does not make one route universally better. It just means the comparison should include real provider access, not only the medicine name.

What a prescriber will assess

A clinician considers the approved indication, medical history, current medicines, safety information, treatment response and the practical requirements of the route. A comparison page can explain the differences and show current provider pricing, but it cannot decide whether a tablet or injection is appropriate.

Switching between routes should be discussed with the prescriber. The oral and injectable dose ladders must not be converted from one format to the other.

What not to compare

A useful tablets-vs-injections comparison does not flatten everything into one score. It should not:

• pretend the dose ladders are interchangeable
• ignore the food-timing rule for tablets
• treat waitlists as the same thing as live access
• claim one route is medically better for everyone